Blood and urine inducible protein 10 as potential markers of disease activity

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 11, 2016, Pages 1554-1561

  Petrone, L ^a   Cannas, A ^a   Vanini, V ^a   Cuzzi, G ^a   Aloi, F ^b,c   Nsubuga, M ^c   Sserunkuma, J ^c   Nazziwa, R A ^c   Jugheli, L ^d,e,f   Lukindo, T ^f   Girardi, E ^a   Antinori, A ^a   Pucci, L ^a   Reither, K ^d,e,f   Goletti, D ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b Italian Association for Solidarity among People (AISPO NGO)   (Uganda)

^c Nsambya Home Care   (Uganda)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f IFAKARA HEALTH INSTITUTE   (Tanzania)

Author keywords

Biomarkers; HIV; Inflammation; Tuberculosis

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; BIOLOGICAL MARKER; CXCL10 PROTEIN, HUMAN; GAMMA INTERFERON; IFNG PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; INTERLEUKIN 6;

ADULT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; TUBERCULOSIS; UGANDA; BLOOD; MIDDLE AGED; URINE; YOUNG ADULT;

ADULT; BIOMARKERS; CD4 LYMPHOCYTE COUNT; CHEMOKINE CXCL10; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; MALE; MIDDLE AGED; TUBERCULOSIS; YOUNG ADULT;

EID: 84992486297     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.16.0342     Document Type: Article

References (34)

1. World Health Organization. Global tuberculosis report, 2015, WHO/HTM/TB/2015.22. Geneva, Switzerland: WHO, 2015.
2. Goletti D, Sanduzzi A, Delogu G. Performance of the tuberculin skin test and interferon-gamma release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J Rheumatol Suppl 2014; 91: 24-31.
3. Ruhwald M, Aabye M G, Ravn P. IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions. Expert Rev Mol Diagn 2012; 12: 175-187.
4. Antonelli A, Ferrari S M, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev 2015; 14: 174-180.
5. Liu C, Cui G, Zhu M, Kang X, Guo H. Neuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptors. Int J Clin Exp Pathol 2014; 7: 8342-8355.
6. Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost 2007; 97: 714-721.
7. Profumo E, Buttari B, Tosti M E, et al. Identification of IP-10 and IL-5 as proteins differentially expressed in human complicated and uncomplicated carotid atherosclerotic plaques. Int J Immunopathol Pharmacol 2010; 23: 775-782.
8. Liu M, Guo S, Hibbert J M, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 2011; 22: 121-130.
9. Sauty A, Dziejman M, Taha R A, et al. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 1999; 162: 3549-3558.
10. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Eugen-Olsen J, Ravn P. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res Notes 2009; 2: 19.
11. Azzurri A, Sow O Y, Amedei A, et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 2005; 7: 1-8.
12. Ruhwald M, Dominguez J, Latorre I, et al. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis (Edinb) 2011; 91: 260-267.
13. Petrone L, Cannas A, Aloi F, et al. Blood or urine IP-10 cannot discriminate between active tuberculosis and respiratory diseases different from tuberculosis in children. Biomed Res Int 2015; 2015: 589 471.
14. Cannas A, Calvo L, Chiacchio T, et al. IP-10 detection in urine is associated with lung diseases. BMC Infect Dis 2010; 10: 333.
15. Djoba Siawaya J F, Ruhwald M, Eugen-Olsen J, Walzl G. Correlates for disease progression and prognosis during concurrent HIV/TB infection. Int J Infect Dis 2007; 11: 289-299.
16. Liovat A S, Rey-Cuille M A, Lecuroux C, et al. Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLOS ONE 2012; 7: e46143.
17. Roberts L, Passmore J A, Williamson C, et al. Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS 2010; 24: 819-831.
18. Keating S M, Golub E T, Nowicki M, et al. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS 2011; 25: 1823-1832.
19. Kamat A, Misra V, Cassol E, et al. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLOS ONE 2012; 7: e30881.
20. Stylianou E, Aukrust P, Bendtzen K, Muller F, Froland S S. Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol 2000; 119: 479-485.
21. Petrone L, Chiacchio T, Vanini V, et al. High urine IP-10 levels associate with chronic HCV infection. J Infect 2014; 68: 591-600.
22. Casrouge A, Decalf J, Ahloulay M, et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 2011; 121: 308-317.
23. Goletti D, Raja A, Ahamed Syed Kabeer B, et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? PLOS ONE 2010; 5: e12577.
24. Kabeer B S, Sikhamani R, Raja A. Comparison of interferon gamma-inducible protein-10 and interferon gamma-based QuantiFERON-TB Gold assays with tuberculin skin test in HIV-infected subjects. Diagn Microbiol Infect Dis 2011; 71: 236-243.
25. Wergeland I, Pullar N, Assmus J, et al. IP-10 differentiates between active and latent tuberculosis irrespective of HIVstatus and declines during therapy. J Infect 2015; 70: 381-391.
26. Vanini V, Petruccioli E, Gioia C, et al. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. J Infect 2012; 65: 49-59.
27. Juffermans N P, Verbon A, van Deventer S J, et al. Elevated chemokine concentrations in sera of human immunodeficiency virus (HIV)-seropositive and HIV-seronegative patients with tuberculosis: A possible role for mycobacterial lipoarabinomannan. Infect Immun 1999; 67: 4295-4297.
28. Kristal B, Shasha S M, Labin L, Cohen A. Estimation of quantitative proteinuria by using the protein-creatinine ratio in random urine samples. Am J Nephrol 1988; 8: 198-203.
29. Price C P, Newall R G, Boyd J C. Use of protein: creatinine ratio measurements on random urine samples for prediction of significant proteinuria: A systematic review. Clin Chem 2005; 51: 1577-1586.
30. Kabeer B S, Raja A, Raman B, et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis 2011; 11: 135.
31. Goletti D, Raja Ahamed A, Kabeer B S, et al. IFN-gamma, but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. J Infect 2010; 61: 133-143.
32. Espindola M S, Lima L J, Soares L S, et al. Dysregulated immune activation in second-line HAART HIV+ patients is similar to that of untreated patients. PLOS ONE 2015; 10: e0145261.
33. Goletti D, Weissman D, Jackson R W, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996; 157: 1271-1278.
34. Graham N M. The role of immunologic and viral markers in predicting clinical outcome in HIV infection. AIDS 1996; 10 (Suppl 5): S21-S25.